[Treatment for rheumatoid arthritis by chemokine blockade]

Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):172-80. doi: 10.2177/jsci.39.172.
[Article in Japanese]

Abstract

Chemokines induce migration of inflammatory cells. In the synovial tissue of rheumatoid arthritis (RA), abundant chemokines are expressed, which contribute migration of lymphocytes and monocytes/macrophages, stimulation of synovial cells, and angiogenesis. Blockade of CCL2, CCL3, CCL5, CCR1, CCR9, CXCL2, CXCL5, CXCL13, CXCL16, CXCR3, CXCR4, CXCR7, and CX3CL1 showed improvement of arthritis of animal models. Moreover, CCR1 antagonist and anti-CXCL10 antibody reduced arthritis of patients with RA. Chemokine is a promising target for RA therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / etiology*
  • Arthritis, Rheumatoid / metabolism
  • Arthritis, Rheumatoid / pathology
  • Cell Movement
  • Chemokine CXCL10 / immunology
  • Chemokines / antagonists & inhibitors*
  • Chemokines / metabolism
  • Disease Models, Animal
  • Humans
  • Inflammation Mediators / antagonists & inhibitors*
  • Inflammation Mediators / metabolism
  • Lymphocytes / pathology
  • Macrophages / pathology
  • Molecular Targeted Therapy
  • Monocytes / pathology
  • Neovascularization, Pathologic
  • Receptors, CCR1 / antagonists & inhibitors
  • Receptors, Chemokine / therapeutic use*
  • Synovial Membrane / blood supply
  • Synovial Membrane / cytology
  • Synovial Membrane / metabolism

Substances

  • Antibodies, Monoclonal
  • CCR1 protein, human
  • Chemokine CXCL10
  • Chemokines
  • Inflammation Mediators
  • Receptors, CCR1
  • Receptors, Chemokine